Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

Key Points

• The aim is to assess the impact of daratumumab-based therapy on patient outcomes in multiple myeloma.
• Multi-center retrospective analysis
• Propensity score matching
• Evaluation of depth of response, progression-free survival, and overall survival
• Daratumumab therapy improved depth of response
• Enhanced progression-free survival (PFS) noted
• Overall survival (OS) benefits observed, although not uniform across all patients